BLA 761109 · Eli Lilly and CO
Lyumjev
Insulin Lispro-Aabc · Injection · Insulin Analog
Last checked: Nov 20, 2026Latest source record: Oct 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jun 15, 2020
Approved uses
3
Original approval plus efficacy supplements
Registered trials
331
68 Phase 3, 9 recruiting
FAERS reports
2,106
454 serious, 35 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 16, 2026.
LYUMJEV ® is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. LYUMJEV ® is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )
Mechanism: The primary activity of LYUMJEV is the regulation of glucose metabolism. Insulins, including insulin lispro-aabc, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 14, 2022 Supplement 4 · Efficacy LetterLabel
- Aug 13, 2021 Supplement 3 · Efficacy LetterLabel
- Jun 15, 2020 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
- LYUMJEV · INSULIN LISPRO-AABC 200UNITS/ML(U-200) · INJECTABLE, INJECTION · Prescription
- LYUMJEV · INSULIN LISPRO-AABC 100UNITS/ML(U-100) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Lispro" as an intervention, any sponsor and status, largest first.
- The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00279201 · 2,091 participants · Start Dec 2005 · Primary completion Nov 2009
Drug: Insulin glargine; Lispro Low Mix and 2 more · For: Diabetes Mellitus, Type 2
Sites: Mobile, Alabama; Litchfield Park, Arizona; Little Rock, Arkansas · 199 sites in all
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational DiabetesPivotal-lookingRecruiting
Ohio State UniversityAcademic, hospital or other
NCT06445946 · 1,572 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 2029
Drug: Metformin; Insulin · For: Gestational Diabetes Mellitus; Pregnancy, High Risk
Sites: Tuscaloosa, Alabama; Los Angeles, California; San Francisco, California · 26 sites in all
- A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without MetforminPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04537923 · 1,428 participants · Start Oct 19, 2020 · Primary completion Oct 11, 2022
Drug: Tirzepatide; Insulin Lispro (U100) · For: Type 2 Diabetes
Sites: Sheffield, Alabama; Fresno, California; Huntington Park, California · 135 sites in all
- A Study of LY900014 in Participants With Type 1 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03214367 · 1,392 participants · Start Jul 17, 2017 · Primary completion Sep 6, 2018
Drug: LY900014; Insulin Lispro and 2 more · For: Type 1 Diabetes Mellitus
Sites: Mobile, Alabama; Concord, California; Escondido, California · 172 sites in all
- A Study in Participants With Type 2 Diabetes MellitusPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01468987 · 1,369 participants · Start Dec 2011 · Primary completion Aug 2013
Drug: LY2605541; Insulin Glargine and 1 more · For: Diabetes Mellitus, Type 2
Sites: Mobile, Alabama; Tucson, Arizona; Little Rock, Arkansas · 156 sites in all
- Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01215955 · 1,117 participants · Start Dec 2010 · Primary completion Jan 2013
Drug: Insulin lispro; Glargine · For: Diabetes Mellitus, Type 2
Sites: Phoenix, Arizona; Concord, California; Fresno, California · 76 sites in all
- Hyperglycemia and Cardiovascular Outcomes With Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00191282 · 1,116 participants · Start Oct 2002 · Primary completion Oct 2007
Drug: Insulin lispro; Human insulin isophane suspension (NPH) and 3 more · For: Diabetes Mellitus, Type 2; Acute Myocardial Infarction
Sites: Toronto, Canada; Zagreb, Croatia; Prague, Czechia · 17 sites in all
- A Study in Participants With Type I Diabetes MellitusPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01454284 · 1,114 participants · Start Jan 2012 · Primary completion Feb 2014
Drug: Glargine; LY2605541 and 1 more · For: Diabetes Mellitus, Type 1
Sites: Concord, California; Fresno, California; La Mesa, California · 119 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased566
- infusion site pain266
- drug ineffective224
- injection site pain224
- wrong technique in product usage process160
- incorrect dose administered148
- blood glucose decreased103
- product dose omission issue71
- visual impairment63
- haemorrhage57
- blood glucose abnormal56
- accidental underdose55
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 78 |
| 2021 | 372 |
| 2022 | 393 |
| 2023 | 340 |
| 2024 | 342 |
| 2025 | 383 |
| 2026 | 194 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lyumjev (Insulin Lispro-Aabc)
2024 spending
$19.9M
Beneficiaries
5,449
17,978 claims
Per beneficiary
$3,657
$24.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $193,210 |
| 2021 | $3,050,167 |
| 2022 | $8,211,586 |
| 2023 | $14,719,969 |
| 2024 | $19,927,368 |
Part B: Lyumjev (Insulin Lispro-Aabc) · HCPCS J1813
2024 spending
$2.0M
Beneficiaries
480
1,433 claims
Per beneficiary
$4,178
2024 ASP limit $15.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $650,022 |
| 2024 | $2,005,639 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
Rosenstock J, Frías JP, Rodbard HW, et al. · JAMA 2023 · Clinical Trial, Phase III, Comparative Study
- Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Dehghani M, Sadeghi M, Barzkar F, et al. · Front Endocrinol (Lausanne) 2024 · Systematic Review, Network Meta-Analysis
- Biosimilars and Novel Insulins.
Ampudia-Blasco FJ · Am J Ther 2020 · Systematic Review
- Ultra-rapid lispro or fast-acting aspart compared to standard insulin lispro and aspart using closed-loop insulin therapy: a systematic review and meta-analysis of randomized control trials.
Rakab MS, Rateb RM, Elsalakawi BH, et al. · Front Endocrinol (Lausanne) 2025 · Systematic Review, Meta-Analysis
- Understanding concentrated insulins: a systematic review of randomized controlled trials.
Ovalle F, Segal AR, Anderson JE, et al. · Curr Med Res Opin 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Fully Closed-Loop Glucose Control Compared With Insulin Pump Therapy With Continuous Glucose Monitoring in Adults With Type 1 Diabetes and Suboptimal Glycemic Control: A Single-Center, Randomized, Crossover Study.
Boughton CK, Hartnell S, Lakshman R, et al. · Diabetes Care 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.